Alcohol use disorder

5 trials 3 recruiting MedDRA PT
5 Registered trials
3 Recruiting
4 Unique sponsors
5 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Phase III: 1 Phase II: 3 Phase I/II: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • Centre Hospitalier Universitaire De Nantes Academic
    PSILOCYBINE
    2025-525069-65-00 1 country 2026 n=172
    Recruiting

Phase II

3 trials
  • Imbrium Therapeutics LP Commercial
    SUNOBINOP TOSILATE
    2024-517105-85-00 1 country 2025 n=100
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    CANNABIDIOL
    2024-518455-28-00 1 country 2024 n=210
    Recruiting
  • Centre Hospitalier Universitaire De Nantes Academic
    PSILOCYBINE
    2023-506647-42-00 1 country 2024 n=30
    Ended

Phase I/II

1 trial
  • University Hospital Of North Norway HF Academic
    KETAMINE; MIDAZOLAM HYDROCHLORIDE
    2023-506052-24-00 1 country 2025 n=34
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Centre Hospitalier Universitaire De Nantes Academic 2 Phase II, Phase III 1
Imbrium Therapeutics LP Commercial 1 Phase II 0
Assistance Publique Hopitaux De Paris Academic 1 Phase II 1
University Hospital Of North Norway HF Academic 1 Phase I/II 1
New trials by year
2024
2
2025
2
2026
1
← All indication landscapes